Press Releases 2010
Date Title
Nov 19, 2010 Agennix AG to Present at Two Investor Conferences in November
Nov 18, 2010 Agennix AG Reports Financial Results For Third Quarter and First Nine Months of 2010
Nov 05, 2010 Agennix Awarded Approximately $490,000 Under U.S. Qualifying Therapeutic Discovery Project Grant Program
Nov 04, 2010 dievini Hopp BioTech Holding and Related Persons and Entities Granted Exemption from Mandatory Tender Offer for Agennix AG
Oct 28, 2010 Agennix AG Schedules Conference Call on November 18, 2010 to Discuss Third Quarter 2010 Financial Results
Oct 01, 2010 Agennix AG Raises Approximately € 76 Million in Net Proceeds
Sep 03, 2010 Agennix AG Announces Data from Talactoferrin Randomized, Double-Blind, Placebo-Controlled Phase II Trial in Severe Sepsis Presented at the Sepsis 2010 International Symposium
Aug 05, 2010 Agennix AG Provides Update on Development of Talactoferrin
Aug 05, 2010 Agennix AG Reports Financial Results for Second Quarter and First Six Months of 2010
Jul 29, 2010 Agennix AG Schedules Conference Call on August 5, 2010 to Discuss First Half of 2010 Financial Results
Jul 23, 2010 Agennix AG Provides Update on Financing Plans
May 17, 2010 Presentation of New Data from Talactoferrin Randomized, Double-Blind, Placebo-Controlled Phase II Trial in Severe Sepsis at ATS
May 14, 2010 Agennix AG to Present at BioEquity Conference
May 12, 2010 Upcoming Data Presentation from Talactoferrin Phase 2 Trial in Severe Sepsis at ATS on May 17
May 06, 2010 Agennix AG Reports Financial Results for First Quarter of 2010
Apr 30, 2010 Agennix AG Schedules Conference Call on May 6, 2010 to Discuss First Quarter 2010 Financial Results
Mar 24, 2010 Agennix AG Reports Financial Results for Fiscal Year 2009
Mar 22, 2010 Agennix AG Schedules Conference Call on March 24, 2010 to Discuss Year-End 2009 Financial Results
Mar 21, 2010 Agennix AG Raises € 9.8 Million (~$13 Million) in Private Placement with Existing Shareholders
Feb 26, 2010 Agennix AG Announces Longer-Term Mortality Results from Talactoferrin Phase 2 Trial in Severe Sepsis
Feb 10, 2010 Agennix AG Announces U.S. Class Action Lawsuit Against Predecessor GPC Biotech AG Fully Closed
Feb 02, 2010 Agennix AG to Present at Close Brothers Seydler Small and Mid Cap Conference in Frankfurt on February 4
Jan 21, 2010 Agennix Expands Talactoferrin Phase 3 FORTIS-M Registration Trial Globally